Crushing Crohn’s

Although Crohn’s disease only affects about 1.3% of the United States population, it has serious and painful symptoms that can make life miserable and bring on life-threatening complications.

Crohn’s disease is an inflammatory bowel disease that eats away at the lining of the digestive tract, causing abdominal pain, diarrhea, weight loss, anemia, and fatigue, often spreading to the deeper parts of the bowels. Crohn’s disease affects each person differently. It can locate itself in various parts of the digestive tract and can cause a range of symptoms from asymptomatic to severe pain and inflammation.

There is currently no known cure for Crohn’s disease. It is often treated with anti-inflammatories and therapy that can bring about long-term remission of the symptoms with continued treatment. The search for a cure for this often debilitating disease never stops, and the expert doctors and researchers at Investigatory Clinical Research (ICR) are at the front of the fight, actively conducting treatment studies daily.

Crohn’s disease

Crohn’s disease is a chronic, progressive disease and new physio-pathological pathways are being discovered every day. The more doctors and researchers can understand how the disease appears and progresses, the greater the opportunity to develop more novel therapies, like testing with Filgotinib. Filgotinib is a drug that is regularly prescribed for the treatment of rheumatoid arthritis. The anti-inflammatory properties of the drug make an ideal candidate for extended research and is showing the potential to reduce inflammation and the remission of Crohn’s disease.

ICR is one of many research groups that are devoting a large portion of their resources towards the elimination and relief of Crohn’s disease symptoms. ICR is using volunteers, aged 18-75, to conduct their research. Males and non-pregnant females of the appropriate age who have never been diagnosed with the disease are ideal candidates for the study.

Patients with severe to moderate symptoms of Crohn’s disease are using Filgotinib in hopes of discovering new pathways toward the remission and cure of the disease. It is important to learn how the implementation of this drug and its anti-inflammatory properties affect all five different forms of Crohn’s disease. Gastroduodenal Crohn’s disease, ileocolitis, ileitis, Jejunoileitis, and Crohn’s colitis are the five different forms of Crohn’s disease, and the team at ICR needs to learn how the treatment affects each form individually in order to have a comprehensive knowledge of the disease. If you would like to be a part of the study, or have any questions, please visit www.icrmd.com.